Skip to main content
. 2007 Aug 23;117(9):2408–2421. doi: 10.1172/JCI31095

Figure 2. FTY720-dependent activation of PP2A and suppression of p210 and p190 BCR/ABL in myeloid and lymphoid cell lines and in CML-BC and Ph1 ALL patient cells.

Figure 2

(A) PP2A assay in untreated (black bars) and FTY720-treated (red bars) 32D-p210BCR/ABL (wild-type and T315I), K562, BaF3-p190BCR/ABL, CML-BCCD34+ (n = 11), and Ph1 ALLCD34+/CD19+ (n = 12); PP2A activity in untreated and FTY720-treated BCR/ABL+ cell lines and primary patient cells is expressed as percentage of the PP2A activity in untreated 32Dcl3 or BaF3 (white bars) and in NBMCD34+ (n = 4) and NBMCD34+/CD19+ (n = 4) cells, respectively. Dot plot shows SET protein levels expressed as arbitrary densitometric units normalized to Grb2 protein levels in NBMCD34+/CD19+ (n = 4) and Ph1 ALLCD34+/CD19+ cells (n = 12) (P < 0.001, Student t-test). (B) p210BCR/ABL and p190BCR/ABL activity and expression in untreated and FTY720-, imatinib-, and 1,9-dideoxyforskolin–treated 32D-p210BCR/ABL (wild-type and T315I), K562, BaF3-p190BCR/ABL, CML-BCCD34+ (n = 3), and Ph1 ALLCD34+/CD19+ cells (n = 6). Grb2 protein levels were detected as control for equal loading. (C) Left: PP2A assay in untreated pBABE-GFP vector–transduced 32Dcl3 (white bar) and 32D-p210BCR/ABL (black bar) cells, small-t–expressing 32Dcl3 and 32D-p210BCR/ABL cells (yellow bars), FTY720-treated 32D-p210BCR/ABL (red bars) and in FTY720-treated small-t–expressing (pBabe-GFP–small-T) 32Dcl3 and 32D-p210BCR/ABL cells (blue bars). Right: Western blots show effect of small-t expression on BCR/ABL activity and expression in untreated and FTY720-treated 32D-p210BCR/ABL cells.